DealsJul 1, 2026, 04:47 PM
Jade Biosciences Licenses Monospecific Antibodies from Paragon
AI Summary
Jade Biosciences, Inc. entered into a worldwide, exclusive license agreement with Paragon Therapeutics, Inc. for monospecific antibodies targeting an undisclosed human disease target. Under the JADE301 License Agreement, Jade Biosciences will pay Paragon up to $22.0 million in development and regulatory milestones, including a $1.5 million fee already paid and a $2.5 million payment for Phase 1 dosing. Additionally, up to $20.1 million in sublicensing fees are due upon commercial milestones, and Jade Biosciences will pay low to mid-single-digit royalties on net sales.
Key Highlights
- Jade Biosciences entered a worldwide, exclusive license agreement with Paragon Therapeutics.
- The agreement covers monospecific antibodies targeting an undisclosed human disease target.
- Jade Biosciences will pay up to $22.0 million in development and regulatory milestones.
- A $1.5 million fee for development candidate nomination was paid in January 2026.
- A $2.5 million milestone is due upon first human patient dosing in a Phase 1 trial.
- Sublicensing fees of up to approximately $20.1 million are tied to commercial milestones.
- Royalties range from low to mid-single-digit percentages on annual net sales.
- Paragon is restricted from new campaigns for the target for at least five years.
Price Impact
More from JBIO